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1. Introduction 
Penile carcinoma is a rare malignancy accounting for 0.4% to 0.6% of all cancers in men in the 
United States and Europe (Perksy, 1977). Penile cancers usually originate from the epithelium 
of the inner prepuce and glans with squamous cell histology accounting for >95% of cancers; 
melanoma and basal cell carcinoma account for another 3% (Cubilla, 2009). There is a 
predictable pattern of spread with the first site of metastasis occurring at the regional femoral 
and iliac nodes (Wood, 2010). The lymphatics of the prepuce connect to the lymphatics from 
the skin of the shaft, and the lymphatics of the glans and corporal bodies join together in the 
superficial inguinal nodes. The superficial lymph nodes drain into the deep inguinal nodes, 
which in turn, drain into the pelvic nodes (internal and external iliac nodes and obturator 
nodes). This lymphatic system is illustrated in Figure 1. Penile lymphatic drainage occurs 
bilaterally through crossover drainage at multiple levels. Direct metastasis to the deep inguinal 
lymph nodes can uncommonly occur, but metastasis directly to the pelvic lymph nodes is rare. 
Histologic subtypes appear to possess different risks of developing metastatic lymph nodes 
with sarcomatoid tumors having the highest risk of around 90% (Cubilla, 2009).  
Once a diagnosis of penile cancer is determined, treatment is based on stage of disease. 
The most recent seventh edition of the TNM staging system for penile carcinoma as 
designated by the American Joint Committee on Cancer is presented in Tables 1 and 2 
(Edge et al., 2010).  
The Netherlands Cancer Institute evaluated the prognostic value of the TNM staging 
classification. The current inconsistencies between staging and prognosis include different 
clinical 5 year disease-specific survival for tumors invading corpus spongiosum and corpora 
cavernosa and no significant differences in the 5-year disease-specific survival between T2 
and T3 tumors or N1 and N2 disease (Leijte et al., 2007). A revision of the current T2 TNM 
staging system to take this prognostic difference into consideration has been proposed.  
2. Treatment overview 
2.1 Local disease 
Treatment, as with other malignancies, is stratified based on staging. For local control, 
surgical amputation is the oncologic gold standard for definitive treatment with local 
recurrence rates ranging from 0-8% (McDougal et al., 1986). Penile tumors with favorable 
histology with Tis, Ta, grade 1 tumors, and certain grade 2 tumors are at lower risk for 
metastases. The goal in these patients is for organ-sparing treatment. These treatment 
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Fig. 1. Lymphatic drainage of the penis (Medical Graphics and Photography, UT M.D. 
Anderson Cancer Center, 2011). 
options include topical therapy, radiotherapy, Mohs surgery, laser ablation, and partial 
penectomy. Surgery, radiation, and laser therapy have not been compared in a randomized 
fashion, and in general, the treatment of choice depends on factors such as tumor size, 
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location, and center experience without noted significant differences in local recurrence rates 
amongst these options (Pagliaro & Crook, 2009; Pizzocaro et al., 2009). Ablative surgery with 
partial penectomy does have a lower risk of local recurrence compared to more conservative 
measures. Proximal tumors or more advanced stages require total penectomy. Appropriate 
treatment is essential and requires a balance between avoiding overtreatment with ensuring 
appropriate removal of all cancerous tissues (Leijte et al., 2007).  
 
Primary Tumor (T)  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Ta Noninvasive verrucous carcinoma 
T1a 
Tumor invades subepithelial connective tissue without 
lymph vascular invasion and is not poorly 
differentiated (i.e., grade 3–4) 
T1b 
Tumor invades subepithelial connective tissue and 
exhibits lymph vascular invasion or is poorly 
differentiated 
T2 Tumor invades corpus spongiosum or cavernosum 
T3 Tumor invades urethra 
T4 Tumor invades other adjacent structures 
Regional Lymph Nodes (N)  
Clinical Stage Definition  
cNX Regional lymph nodes cannot be assessed 
cN0 No palpable or visibly enlarged inguinal lymph nodes 
cN1 Palpable mobile unilateral inguinal lymph node 
cN2 
Palpable mobile multiple or bilateral inguinal lymph 
nodes 
cN3 
Palpable fixed inguinal nodal mass or pelvic 
lymphadenopathy unilateral or bilateral 
Pathologic Stage Definition  
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Metastasis in a single inguinal lymph node 
pN2 Metastasis in multiple or bilateral inguinal lymph nodes 
pN3 
Extranodal extension of lymph node metastasis or 
pelvic lymph nodes(s) unilateral or bilateral 
Distant Metastasis (M)  
M0 No distant metastasis 
M1 Distant metastasis* 
*Lymph node metastasis outside the true pelvis in addition to visceral or bone sites. 
Table 1. Definitions of TNM (AJCC, 2010) Used with the permission of the American Joint 
Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the 
AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science and 
Business Media LLC, www.springer.com. 
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Stage 0 Tis N0 M0 
 Ta N0 M0 
Stage I T1a N0 M0 
Stage II T1b N0 M0 
 T2 N0 M0 
 T3 N0 M0 
Stage IIIa T1-3 N1 M0 
Stage IIIb T1-3 N2 M0 
Stage IV T4 Any N M0 
 Any T N3 M0 
 Any T Any N M1 
Table 2. Stage Grouping for Penile Cancer (AJCC, 2010) Used with the permission of the 
American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this 
material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer 
Science and Business Media LLC, www.springer.com. 
2.2 Nodal disease 
Metastatic disease in the inguinal region is the most important prognostic factor for survival 
in penile squamous cell carcinoma. The presence of palpable inguinal lymph nodes is not a 
definitive indicator of metastatic disease as it may also be secondary to inflammation in as 
many as 50% of cases at the time of initial diagnosis (Pizzocaro et al., 2009). Likewise, occult 
metastatic disease can escape detection, and multiple studies have shown an incidence of 
lymph node metastases in up to 40% of patients who are clinically node negative (Delacroix 
& Pettaway, 2010). Utilization of imaging with ultrasound, CT, and MRI may identify 
distortion of lymph node architecture; however, they are also not completely reliable in 
differentiating between causes (Heyns, 2010b).  
Clinical features that suggest advanced regional disease include size of inguinal lymph 
nodes greater than 4 cm, bilateral and multiple enlarged nodes, overlying skin changes, and 
enlarged pelvic lymph nodes (Delacroix & Pettaway, 2010). Pathologically, the most 
important prognostic factors for lymph node spread include tumor grade, lymphovascular 
invasion, perineural invasion, pathological subtype, tumor depth or thickness, anatomic site, 
size, and growth pattern, with the first three factors being the most predictive (Cubilla, 2009; 
Pagliaro, 2011; Pagliaro & Crook, 2009). 
The optimal management in patients without inguinal adenopathy consists of a variety of 
approaches to the lymph nodes including surveillance, fine needle aspiration cytology, 
dynamic sentinel lymph node biopsy, and different variations of lymphadenectomies 
(Graafland, 2010; Heyns, 2010a). Lymphadenectomies are divided into early versus delayed, 
with early lymphadenectomy defined as within 6 weeks after treatment of the primary 
tumor and delayed defined as therapeutic after the development of palpable nodes during 
follow-up. Johnson and Lo compared early versus late therapeutic inguinal lymph node 
dissection and reported a 3-year survival rate of 71% versus 57% and a 5-year survival rate 
of 50% versus 30% favoring the early group (Johnson & Lo, 1984). This benefit is likely due 
to the incidence of clinically occult metastatic disease and suggests that surgery with 
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microscopic disease rather than bulky nodal disease leads to fewer post-operative 
complications and results in improved overall survival. However, lymphadenectomy does 
also come with significant morbidities and an associated mortality of 3%, high costs for the 
approximately 80% of clinically node negative patients who will be free of lymph node 
involvement (Pagliaro & Crook, 2009; Heyns, 2010a).  
The survival in patients with established lymph node metastases after surgical dissection is 
variable from 20-60%, a range that correlates with the extent of metastatic disease (Heyns, 
2010a; Pagliaro, 2011). Metastatic enlargement of the regional nodes can lead to morbidity 
with skin necrosis and chronic infection; death, which usually occurs within two years if left 
untreated, can occur from hemorrhage, sepsis, and failure to thrive. However, unlike many 
other malignancies, regional nodal metastatic disease can be cured with lymphadenectomy 
alone in appropriately selected patients (Delacroix & Pettaway, 2010).  
2.3 Prognostic factors for combined modality consideration 
Overall, the pathologic features that are associated with long term survival after attempted 
curative lymphadenectomy include the following: two or fewer lymph nodes involved, 
unilateral involvement, no extranodal extension, and absence of pelvic nodal metastases 
(Pagliaro, 2011). Once bilateral or pelvic lymph nodes are involved (stage N2 or N3 disease), 
the 5-year overall and disease-free survival rates drop to only 10-20% and are even more 
dismal with the presence of extranodal extension (Pizzocaro, 1996).  
When lymph nodes are initially fixed, chemotherapy is a rational upfront strategy since 
surgery would be difficult. In the absence of distant metastases, select patients may be 
candidates for neoadjuvant therapy in the hopes of downstaging to operable disease with 
curative intent (Leijte, 2007). 
3. Combined modality management 
3.1 Chemotherapy response rates 
Neoadjuvant chemotherapy for solid tumors requires that there be chemotherapeutic drugs 
or combinations that exceed a certain threshold of efficacy. Historically, the treatments were 
first found to have high response rates in the setting of advanced metastatic disease, then 
tested in the adjuvant or neoadjuvant setting. For the treatment of advanced metastatic 
penile cancer, various combinations were studied and most had only modest response rates. 
The activity of combination cisplatin and 5-fluorouracil was first reported by Hussain et al 
in 1990 where 5 advanced penile squamous cell carcinoma patients were treated with 
sequential cisplatin and 5-fluorouracil, all five achieved partial response, and one even 
improved to resectable disease (Hussain et al., 1990). Double agent cisplatin and irinotecan 
was studied in the phase II EORTC 30992 trial that evaluated 26 patients with T3, T4, N1, 
N2, N3 or M1 disease. Of these 26 patients, 7 were treated in the neoadjuvant setting. They 
had 8 total responses, 2 CRs and 6 PRs with 3 of the patients receiving neoadjuvant 
chemotherapy proceeding to lymphadenectomy having pathologically negative lymph 
nodes. The overall response rate was 30.8% (Theodore et al., 2008). 
The most studied triple-drug regimen is cisplatin, methotrexate, and bleomycin. Dexeus et 
al initially described this regimen with a response in 10 of 14 patients, including 2 CRs 
(Dexeus et al., 1991). Additional studies by Haas, Hakenberg, Corral, and Leijte found 
responses, but at the expense of significant hematological and pulmonary toxicities (Protzel 
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& Hakenberg, 2009). Newer regimens have better toxicity profiles and higher response rates. 
Bleomycin is no longer recommended for the treatment of penile cancer. 
3.2 Neoadjuvant chemotherapy 
The literature regarding neoadjuvant chemotherapy for penile cancer is limited with the first 
prospective series just recently published (Pagliaro et al., 2010). There have been seven 
retrospective studies assessing the role of neoadjuvant chemotherapy in cases of fixed inguinal 
lymph nodes (Protzel & Hakenberg, 2009). Pizzocaro et al were able to achieve partial 
responses with neoadjuvant chemotherapy in 9 of 16 patients (56%) followed by 
lymphadenectomy with the best results achieved with a cisplatin/5-fluorouracil combination 
(Pizzocaro et al., 1996). Leijte et al studied 20 patients with initially unresectable penile 
cancer who received neoadjuvant chemotherapy at the Netherlands Cancer Institute 
between 1972 and 2005. Several regimens were sequentially used throughout that time 
period including: single agent bleomycin until 1985, then bleomycin, vincristine, and 
methotrexate until 1999, then cisplatin and 5-fluorouracil until 2001, and cisplatin, 
bleomycin, and methotrexate since 2001, with one patient treated with cisplatin and 
irinotecan in a clinical trial. Twelve patients had a clinical response to chemotherapy (2 
complete, 10 partial), and 8 of the 9 patients who went on to resection with curative intent 
were clinically disease-free at median follow-up time of 20 months (Leijte et al., 2007). 
There was a significant difference in overall survival in those who responded to 
chemotherapy (56% overall survival at 5 years) compared to the nonresponders with 
stable or progressive disease through treatment (0% overall survival at 5 years) due to 
recurrence after consolidative surgery as shown in Figure 2 (Leijte et al., 2007).  
 
 
 
 
 
 
 
Fig. 2. Overall survival of patients grouped according to response to neoadjuvant 
chemotherapy (Reproduced from Leijte et al, 2007, with permission). 
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In another retrospective study, Bermejo et al reviewed 10 patients with advanced penile 
carcinoma treated from 1985 to 2000 who had received consolidation surgery after having 
stable, partial, or complete responses on various chemotherapy regimens. After receiving 
induction regimens consisting of paclitaxel/ifosfamide/cisplatin, bleomycin/methotrexate/ 
cisplatin, and paclitaxel/carboplatin, the authors found that 4 patients achieved CR, 1 
achieved PR, and 5 had stable disease after chemotherapy with responses tending to occur 
quickly during treatment, often after the first or second cycles. After surgical 
consolidative lymphadenectomy, pathology revealed that 3 patients had no evidence of 
metastatic disease in the lymph nodes, with all 3 of these patients having had received 
paclitaxel, ifosfamide, and cisplatin as their neoadjuvant regimen (Bermejo, 2007). Culkin 
and Beer’s literature review of cisplatin-based neoadjuvant chemotherapy found a clinical 
response in 69% with 23% of patients having no disease in follow-up after surgery. In 
summary, these authors found that neoadjuvant chemotherapy could render patients 
disease-free, and in combination with surgical consolidation, could lead to prolonged 
survival of patients with advanced penile cancer with low toxicity in regards to surgical 
complications (Culkin & Beer, 2003).  
The design of the first prospective study of neoadjuvant chemotherapy for metastatic 
penile cancer was based on data related to efficacy of paclitaxel, ifosfamide, and cisplatin 
in head and neck squamous cell carcinoma (Pagliaro et al., 2010). Thirty patients with 
clinical stage N2 or N3 disease without evidence of distant metastases were enrolled into 
a phase II trial of which twenty-three (76.7%) completed four courses of neoadjuvant 
chemotherapy. N2 and N3 disease was defined by the 1987 to 2002 TNM staging system 
as palpable, mobile, multiple or bilateral inguinal lymph nodes (N2) or fixed inguinal 
nodal mass or pelvic lymphadenopathy, unilateral or bilateral (N3). The four cycles were 
on 21 to 28-day durations depending on count recovery, and paclitaxel was dosed at 
175mg/m2 over 3 hours on day 1, ifosfamide 1200mg/m2 IV over 2 hours on days 1-3, and 
cisplatin 25mg/m2 IV over 2 hours on days 1-3. Twenty-two patients went on to 
subsequent surgery with bilateral inguinal lymph node dissection and either unilateral or 
bilateral pelvic lymph node dissection. Three patients (13.6% of those who completed the 
treatment) had no tumor remaining in the surgical specimen, and 11 patients (36.7% of 
those enrolled) survived without recurrence, with median follow-up of 34 months at the 
time of publication (Figure 3A). A total of 3 CRs and 12 PRs were achieved for an overall 
response rate of 50%.  
Figure 3A-B shows an estimated median time to progression of 8.1 months, ranging from 5.4 
months to greater than 50 months and an overall survival of 17.1 months, ranging from 10.3 
months to greater than 60 months. Univariate analysis showed significantly worse time to 
tumor progression and overall survival among the patients who did not have an objective 
response to chemotherapy (Figure 3C-D), had bilateral residual tumor at resection, or had 
extranodal extension detected after chemotherapy (Pagliaro et al, 2010).  
This study determined the outcomes of a specific multimodality approach with neoadjuvant 
chemotherapy and surgical consolidation; however, it was not randomized and thus was 
not designed to demonstrate superiority over surgery. However, from the previously 
published series of penile carcinoma with stage TX, N2-3, M0 disease that document the 
progression-free and overall survival, as previously mentioned, long-term, disease-free 
survival was seldom achieved with surgery alone. Based on other series, the estimated 
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long-term survival for patients with pelvic lymph node metastases and/or extranodal 
extension was only 10-15% with surgery alone. Importantly, there also were no 
chemotherapy-related deaths or increased surgical morbidity or mortality following this 
neoadjuvant regimen as compared to the effective, yet toxic, bleomycin, methotrexate, 
cisplatin regimen.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Overall and progression-free survival for patients treated with neoadjuvant 
paclitaxel, ifosfamide, and cisplatin chemotherapy (Reproduced from Pagliaro et al, 2010, 
with permission). 
In a special commentary by Pettaway et al, the authors recommend that neoadjuvant 
chemotherapy should be considered with N1 disease with mobile mass greater than 4 cm, 
N2-N3 disease, or recurrent regional disease after therapeutic lymph node dissection 
(Pettaway et al., 2010). This algorithm is demonstrated in Figure 4.  
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Fig. 4. Algorithm for management of bulky lymph node metastases (Reproduced from 
Pagliaro and Crook 2009, with permission). 
3.3 Post-chemotherapy surgery 
Surgical techniques include radical inguinal lymphadenectomy, the gold standard for 
inguinal metastasis where all lymph nodes in the superficial and deep compartments of the 
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inguino-femoral region are removed, and pelvic lymphadenectomy when indicated 
depending on degree of inguinal disease (Pettaway et al., 2010). Chemotherapy has not yet 
been assessed in a neoadjuvant setting for an aim of organ-sparing surgery. There are also 
no data in regards to using radiation as consolidation treatment in metastatic penile cancer 
at this time though it is a promising thought given its utility in other squamous cell 
carcinomas (NCCN, 2010).  
3.4 Adjuvant chemotherapy 
Little literature exists regarding adjuvant chemotherapy. In a Pizzocaro et al study of 12 
patients who received adjuvant vincristine, bleomycin, and methotrexate, only 1 
developed progression with a mean remission time of 42 months (Pizzocaro & Piva, 1988). 
In another Pizzocaro study, the 5-year survival was 82% after adjuvant chemotherapy 
compared to only 37% in  historical controls without adjuvant treatment (Pizzocaro et al., 
1996). In Hakenberg’s study, mean duration of remission with adjuvant cisplatin, 
bleomycin, and methotrexate was only 26 months with 1 treatment-associated death 
(Hakenberg et al., 2006).  
3.5 The role of radiotherapy 
Radiation in the neoadjuvant setting has not been studied in detail. A retrospective series 
in India looked at 77 patients over a 20 year period who had palpable pathological node 
positive disease at least 4 cm in size. Thirty-four of these patients received 40 Gy/4 weeks 
of radiation followed by consolidative surgery. The irradiated patients had less extranodal 
extension (9% versus 33%) with a 70% 5 year disease-free survival. However, there was 
high morbidity with this approach with local complication rate of 100% with skin necrosis 
or infection (Ravi et al., 1994).  
4. Conclusion 
Squamous cell carcinoma of the penis is an uncommon disease, which essentially precludes 
randomized clinical studies. The prognosis for metastatic penile carcinoma is known to be 
very poor with either surgery or chemotherapy alone. Evidence from a recent prospective 
study (Pagliaro et al, 2010) showed promising results with a multimodal approach with the 
paclitaxel, ifosfamide, and cisplatin chemotherapy regimen before surgery for curative 
intent in metastatic disease. This disease truly necessitates a multidisciplinary approach in 
prognostication and management of these patients to improve survival while reducing 
morbidity or mortality of unnecessary procedures. Not only are members of medical 
oncology and urology involved, but wound care and plastic surgery specialists have 
important roles. This now represents a reasonable standard of care for the treatment of 
regional metastatic disease. 
Future directions should include additional studies to promote the further understanding of 
the utility of neoadjuvant chemotherapy in lower stage disease that may lead to improved 
organ-sparing, predictive factors for chemotherapy response, possible addition of biologic 
agents, role of radiation, and measures to decrease the morbidity of surgery. Squamous cell 
carcinoma of the penis is now becoming a multidisciplinary disease with many exciting 
opportunities on the horizon.  
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